Insulet Corp. (PODD) Misses Q1 EPS by 1c, Offers Q2, FY Rev. Guiance

Insulet Corp. (NASDAQ: PODD) reported Q1 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $61.2 million versus the consensus estimate of $68.2 million.

Insulet Corp. sees FY2015 revenue of $305-320 million, versus the consensus of $312.57 million.

Insulet Corp. sees FY2015 revenue of $67-70 million, versus the consensus of $75.32 million.

For earnings history and earnings-related data on Insulet Corp. (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M